LPCN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LP

Mkt Cap

$13.0M

Volume

387.28K

Next Earnings

November 5th

Loading chart

LP

LPCNLipocine Inc.

LPCN

Pay with—

Available Balance0.00

LP

Mkt Cap

$13.9M

Volume

387.28K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Here's Why You Should Add LPCN Stock to Your Portfolio NowLipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis.Zacks Investment Research · Oct 8, 2026

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment MilestoneLipocine announced 80% enrollment completion in its Phase 3 clinical trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is on track for topline results in Q2 2026, with 66 of 80 planned participants randomized.Benzinga · Dec 16, 2025

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment ConferenceLipocine Inc. announced it will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, showcasing its proprietary oral drug delivery technology and clinical development candidates.Benzinga · Sep 5, 2025

Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightThe sarcopenia market remains largely untapped, with significant unmet medical needs and no approved drug therapies. However, pharmaceutical interest is rising, particularly around muscle-enhancing agents and anti-inflammatory pathways. Regulatory bodies are beginning to recognize sarcopenia as a distinct clinical condition, which may streamline future drug approvals.GlobeNewswire Inc. · Apr 24, 2025

Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss FormulaLipozem, a turmeric-based supplement, claims to address the root cause of stubborn weight gain - inflammation within fat cells. Consumer reports highlight remarkable weight loss results, with some users losing over 90 lbs in just 3 months. The supplement's unique formula, developed by Dr. Julian Ross, targets inflammation directly, enabling natural and sustained fat burning.GlobeNewswire Inc. · Mar 21, 2025

Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii BiosciencesThe report provides an in-depth analysis of the Postpartum Depression (PPD) pipeline, showcasing insights into more than ten diverse companies and over ten pipeline drugs. It highlights innovative therapeutic candidates, including RE-104 by Reunion Neuroscience and GH001 by GH Research, and their potential impact on PPD treatment paradigms.GlobeNewswire Inc. · Mar 4, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsightThe depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.GlobeNewswire Inc. · Feb 25, 2025

Light Vision 2024 Shenzhen International Optics FairThe Shenzhen International Eye Industry Expo 2024 was held from December 27th to 29th, attracting over 150 well-known brands and 20,000 professional visitors. The expo featured various exhibition areas showcasing new products, technologies, and trends in the global eyewear industry.GlobeNewswire Inc. · Dec 31, 2024

Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's WhyLipocine (LPCN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.Zacks Investment Research · Jun 6, 2024

Here's Why Momentum in Lipocine (LPCN) Should Keep goingLipocine (LPCN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.Zacks Investment Research · May 21, 2024

to start trading

LP

LPCNLipocine Inc.

LPCN

Pay with—

Available Balance0.00

Your PositionYou don't own any LPCN yet.

Related Tickers

Earnings